{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:31:00Z","timestamp":1791721860466,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejca.2025.115755","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:26:24Z","timestamp":1757348784000},"page":"115755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis"],"prefix":"10.1016","volume":"229","author":[{"given":"Mario","family":"Mandal\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ugolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Caldirola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Rulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Sini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Simi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Costabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bellezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guadagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gianatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ghiorzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Massi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2025.115755_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115755_bib2","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2025.115755_bib3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","article-title":"Hallmarks of resistance to Immune-Checkpoint inhibitors","volume":"10","author":"Karasarides","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.ejca.2025.115755_bib4","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-18-2652","article-title":"Multiplex quantitative analysis of Tumor-Infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma","volume":"25","author":"Wong","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115755_bib5","article-title":"Using global gene expression to discriminate thin melanomas with poor outcomes","volume":"4","author":"Hothem","year":"2016","journal-title":"Mol Cell Oncol"},{"issue":"7528","key":"10.1016\/j.ejca.2025.115755_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejca.2025.115755_bib7","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2025.115755_bib8","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/annonc\/mdv255","article-title":"The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600","volume":"26","author":"Massi","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115755_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"10.1016\/j.ejca.2025.115755_bib10","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41374-021-00653-y","article-title":"Establishing standardized immune phenotyping of metastatic melanoma by digital pathology","volume":"101","author":"Sobottka","year":"2021","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.ejca.2025.115755_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s40425-019-0797-4","article-title":"The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors","volume":"7","author":"Massi","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.115755_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/cells10020422","article-title":"Digital immunophenotyping predicts disease free and overall survival in early stage melanoma patients","volume":"10","author":"De Logu","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ejca.2025.115755_bib13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.115755_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ceb.2017.05.006","article-title":"Metabolism shapes the tumor microenvironment","volume":"48","author":"Reina-Campos","year":"2017","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115755_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejca.2025.115755_bib16","article-title":"Role of hypoxia in the tumor microenvironment and targeted therapy","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115755_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"9","key":"10.1016\/j.ejca.2025.115755_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004884","article-title":"Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2025.115755_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/0284186X.2023.2248371","article-title":"Intra-patient evolution of tumor microenvironment in the pathogenesis of treatment-na\u00efve metastatic melanoma patients","volume":"62","author":"Kohtam\u00e4ki","year":"2023","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2025.115755_bib20","doi-asserted-by":"crossref","unstructured":"Falcone I., Conciatori F., Bazzichetto C., et al. Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy. Cancers (Basel). 202; 12(10):2870.","DOI":"10.3390\/cancers12102870"},{"issue":"5","key":"10.1016\/j.ejca.2025.115755_bib21","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ejca.2025.115755_bib22","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2025.115755_bib23","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.115755_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/labinvest.2016.132","article-title":"Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation","volume":"97","author":"Mandal\u00e0","year":"2017","journal-title":"Lab Invest"},{"issue":"17","key":"10.1016\/j.ejca.2025.115755_bib25","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/0008-5472.CAN-18-0365","article-title":"Oncogenic BRAFV600E governs regulatory T-cell recruitment during melanoma tumorigenesis","volume":"78","author":"Shabaneh","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.115755_bib26","doi-asserted-by":"crossref","unstructured":"Miao W., Li L., Liu X., et al. A targeted quantitative proteomic method revealed a substantial reprogramming of kinome during melanoma metastasis. Sci Rep. 202; 10(1):2485.","DOI":"10.1038\/s41598-020-59572-5"},{"issue":"5","key":"10.1016\/j.ejca.2025.115755_bib27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1541-7786.MCR-07-0344","article-title":"Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases","volume":"6","author":"Xu","year":"2008","journal-title":"Mol Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T09:50:30Z","timestamp":1772877030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925005404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"alternative-id":["S0959804925005404"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115755","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115755"}}